Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 14/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 10/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 7/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 7/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL584371 | 0.99 | STAT3 (0.49) | STAT3STAT1CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL12057391 | 0.95 | STAT3 (0.46) | STAT3STAT1CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL15693592 | 0.92 | STAT3 (0.45) | STAT3STAT1CHRNA7CHRNB4CHRNA3 | |
| Exeporfinium SCHEMBL585997 | 0.89 | STAT3 (0.52) | STAT3STAT1CHRNA7CHRNB4CHRNA3 | |
| Exeporfinium SCHEMBL5012396 | 0.88 | STAT3 (0.51) | STAT3STAT1CHRNA7CHRNB4CHRNA3 | |
| Exeporfinium SCHEMBL584418 | 0.88 | STAT3 (0.51) | STAT3STAT1CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL13380379 | 0.88 | STAT3 (0.43) | STAT3STAT1CHRNA7CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL29648896 | 0.86 | STAT3 (0.48) | STAT3STAT1CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL21523873 | 0.86 | STAT3 (0.53) | STAT3STAT1TERTLMNAPOLB | |
| SCHEMBL15673545 | 0.85 | STAT3 (0.46) | STAT3STAT1CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | claimed |
| EP-2355816-B1 | PORPHYRIN COMPOUNDS FOR KILLING, INHIBITING OR PREVENTING THE GROWTH OF MICROBIAL BIOFILMS | DESTINY PHARMA LTD (GB) | 2014-05-14 | — | — | EP | claimed |
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | claimed |
| US-20110262511-A1 | Novel Uses | DESTINY PHARMA LIMITED (GB) | 2011-10-27 | — | — | US | claimed |
| EP-2355816-A2 | NOVEL USES | Destiny Pharma Limited (GB) | 2011-08-17 | — | — | EP | claimed |
| WO-2010046663-A2 | NOVEL USES | DESTINY PHARMA LIMITED (GB) | 2010-04-29 | — | — | WO | claimed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | claimed |
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2355816-B1 | PORPHYRIN COMPOUNDS FOR KILLING, INHIBITING OR PREVENTING THE GROWTH OF MICROBIAL BIOFILMS | DESTINY PHARMA LTD (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110262511-A1 | Novel Uses | DESTINY PHARMA LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110262511-A1 | Novel Uses | DESTINY PHARMA LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | DESTINY PHARMA LIMITED | 2007-12-06 | — | — | US | disclosed |
| US-20070167619-A1 | Novel uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262511-A1 | Novel Uses | XDH, F12, ZFX | STAT3 2084/4885STAT1 1133/4885CHRNA7 4821/4885 |
| US-20070167619-A1 | Novel uses of porphyrin compounds | PPOX, ZFX, ZYX | STAT3 529/4885STAT1 176/4885CHRNA7 4878/4885 |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | PPOX, PPIF, TYR | STAT3 2340/4885STAT1 1254/4885CHRNA7 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.